Recent Immunological Findings in Hodgkin's Disease -

Lymphocytotoxic serum factors and lymphocyte functions in untreated Hodgkin's disease

The prevalence of complement dependent, cold-reactive lymphocytotoxic serum factors (LT) was studied in 80 untreated patients with Hodgkin's disease by a microcytotoxicity assay. Sera from 24 patients (30%) contained LT as judged from at least 50% lysis of lymphocytes from 16 to 23 randomly selected normal donors. The spontaneous incorporation of 14C-thymidine into blood lymphocytes from patients with LT was significantly higher than that of lymphocytes from LT-negative patients and from healthy controls. Total lymphocyte and T-cell counts, Concanavalin A, and pokeweed mitogen-induced lymphocyte DNA synthesis were lower in patients with LT. Lymphocytotoxic sera were more frequently encountered in patients with B symptoms, advanced disease, or nodular sclerosis/lymphocyte predominance histopathologic characteristics. LT were often found in patients with large and tumor-involved spleens. The ability of patient's serum to inhibit control lymphocyte response to Concanavalin A stimulation did not differ between LT-positive and LT-negative patients. We conclude that the presence of LT is associated with a quantitative and qualitative impairment of blood T-lymphocytes in untreated patients with Hodgkin's disease.

The effect of in vitro irradiation on mitogenic responsiveness of peripheral blood lymphocytes from patients with untreated and cured Hodgkin's disease

Blood lymphocytes from 10 untreated patients with active Hodgkin's disease were compared with those of 10 cured patients with regard to the responsiveness of the cells to PHA and Con A following in vitro irradiation. Lymphocytes of patients remaining in long-term remission exhibited the same pattern of radiosensitivity as those of healthy donors: there was one relatively radiosensitive cell population and one relatively resistant. The latter cell population was undetectable in patients with an active disease. Reappearance of the radioresistant PHA and Con A reactive cell fractions might thus be associated with remission.

T and B-RFC inhibiting factor in plasma from patients with active Hodgkin's disease

We report the presence of a rosette inhibiting factor (RIF) in the plasma of patients with active Hodgkin's disease. This factor suppresses the rosette forming ability of autologous Active T, Total T, and B lymphocytes with sheep red blood cells, and tends to disappear when clinical remission is achieved. To a lesser extent, the RIF also lowers the Active T, Total T and B-RFC percentages of lymphocytes obtained from normal donors. Although carcinoma and non-Hodgkin's lymphoma patients, as a group, did not exhibit rosette inhibitive properties, certain individuals with these diagnoses did show isolated RIF activity. The RIF could be adsorbed out of plasma using peripheral blood lymphocytes (PBL) from normal controls and appears to be a large heat stable molecule which does not affect PBL viability.

Interaction between serum factors and T lymphocytes in Hodgkin's disease. Use as a diagnostic test

We studied the mechanism of defective binding of sheep erythrocytes to the surface of peripheral blood T lymphocytes (E-rosette-formation) in Hodgkin's disease. The decreased percentage of E-rosette-forming cells (range, 21 to 77 per cent) in 25 patients with Hodgkin's disease was reversed and returned to normal range (52 to 78 per cent) by prior incubation of the T lymphocytes in tissue-culture medium with 20 per cent fetal-calf serum for 18 to 24 hours. The percentage of E-rosette-forming cells was suppressed by additional incubation with serum from patients with Hodgkin's disease (range, 20 to 61 per cent) but not with serum from patients with other neoplasms or from normal subjects (range, 52 to 74 per cent). Only target T lymphocytes from patients with Hodgkin's disease were suppressed by Hodgkin-disease serum. The findings suggest that there is a specific interaction between serum factors and the surface of peripheral blood T lymphocytes in Hodgkin's disease.